Age-related maculopathy susceptibility protein 2 is a mitochondrialprotein that in humans is encoded by the ARMS2gene.[3][4][5] The ARMS2 protein is closely linked to the ARMS2 gene. The ARMS2 gene is a genetic risk factor for age-related macular degeneration (AMD). The exact biological mechanism of the ARMS2 protein is not fully understood, but studies of protein transport and variants have indicated that the protein plays a role in processes that impact the retina.[6]
Cellular transport
The ARMS2 protein undergoes a process to move from inside the cell to the extracellular matrix of the choroid eye layer. This process is one that accounts for the small 11 kDa molecular weight of the ARMS2 protein. The process of which the ARMS2 protein exits the cell is through the use of the chaperone proteins calnexin and calreticulin. The ARMS2 protein is able to recruit the chaperones from the cytosol. This is different from the other known processes of protein secretion which is usually facilitated by the Endoplasmic Reticulum and Golgi Body. The lack of the N-terminal leading sequence contributes to this process. Without the presence of chaperone proteins the ARMS2 proteins are not excreted from the cell.[7]
Variants
The ARMS2 protein is impacted by the expression of the ARMS2 gene located on chromosome 10q26. The ARMS2 locus is associated with risk factors that connected to the development of age related macular degeneration (AMD). This gene was detected in human retinal pigment epithelial cells (ARPE-19) through immunofluorescence and reverse transcriptase PCR.[8]
When variants of the gene are expressed they cause the development of mutated ARMS2 proteins, that fail to exit the cell due to the lack of favorable interactions with chaperone proteins, this lack of interaction causes the ARMS2 protein to lack proper tertiary structures.[7] ARMS2 protein translation is also impacted by the addition of risk variants experimentally, specifically it is notable that AMD risk haplotype leads to lower levels of ARMS2 mRNA transcription, which results in lower levels of ARMS2 protein translation and availability in the cell. A specific mutation in the 3'-untranslated region of ARMS2 causes this impact as it controls mRNA stability.[9]
Despite the determination of ARMS2 expression decreasing with the addition of AMD-associated risk variants there is still no concrete evidence that the development of age-related macular degeneration (AMD) is caused by the low levels of ARMS2 protein.[9]
^Pan Y, Fu Y, Baird PN, Guymer RH, Das T, Iwata T (November 2023). "Exploring the contribution of ARMS2 and HTRA1 genetic risk factors in age-related macular degeneration". Progress in Retinal and Eye Research. 97 101159. doi:10.1016/j.preteyeres.2022.101159. PMID36581531.
^ abKortvely E, Hauck SM, Behler J, Ho N, Ueffing M (August 2016). "The unconventional secretion of ARMS2". Human Molecular Genetics. 25 (15): 3143–3151. doi:10.1093/hmg/ddw162. PMID27270414.
Shastry BS (2006). "Further support for the common variants in complement factor H (Y402H) and LOC387715 (A69S) genes as major risk factors for the exudative age-related macular degeneration". Ophthalmologica. 220 (5): 291–295. doi:10.1159/000094617. PMID16954704. S2CID30250011.
Tanimoto S, Tamura H, Ue T, Yamane K, Maruyama H, Kawakami H, et al. (February 2007). "A polymorphism of LOC387715 gene is associated with age-related macular degeneration in the Japanese population". Neuroscience Letters. 414 (1): 71–74. doi:10.1016/j.neulet.2006.12.011. PMID17194541. S2CID19228896.
Francis PJ, George S, Schultz DW, Rosner B, Hamon S, Ott J, et al. (2007). "The LOC387715 gene, smoking, body mass index, environmental associations with advanced age-related macular degeneration". Human Heredity. 63 (3–4): 212–218. doi:10.1159/000100046. PMID17347568. S2CID43821054.
Kondo N, Honda S, Ishibashi K, Tsukahara Y, Negi A (October 2007). "LOC387715/HTRA1 variants in polypoidal choroidal vasculopathy and age-related macular degeneration in a Japanese population". American Journal of Ophthalmology. 144 (4): 608–612. doi:10.1016/j.ajo.2007.06.003. PMID17692272.
Wiggs JL (September 2007). "Macular degeneration: risk factors for progression". Archives of Ophthalmology. 125 (9): 1264–1265. doi:10.1001/archopht.125.9.1264. PMID17846368.
Brantley MA, Fang AM, King JM, Tewari A, Kymes SM, Shiels A (December 2007). "Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab". Ophthalmology. 114 (12): 2168–2173. doi:10.1016/j.ophtha.2007.09.008. PMID18054635.
Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.
The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.